Edition:
India

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

4,015JPY
18 Jun 2018
Change (% chg)

¥-2 (-0.05%)
Prev Close
¥4,017
Open
¥4,015
Day's High
¥4,050
Day's Low
¥3,992
Volume
1,409,700
Avg. Vol
2,224,257
52-wk High
¥4,241
52-wk Low
¥2,284

Select another date:

Wed, May 9 2018

MEDIA-Delhi HC orders sale of Shivinder Singh's unencumbered listed shares in Daiichi Sankyo case - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

BRIEF-Daiichi Sankyo to reorganize Kitasato Daiichi Sankyo Vaccine into specialized manufacturing unit

* Says it plans to reorganize unit Kitasato Daiichi Sankyo Vaccine Co., Ltd. into a unit specializing in manufacturing, effective April 1, 2019

BRIEF-‍Daiichi Sankyo And Darwinhealth Enter Exclusive Research Collaboration For Novel Cancer Target Initiative​

* ‍DAIICHI SANKYO AND DARWINHEALTH ENTER EXCLUSIVE RESEARCH COLLABORATION FOR NOVEL CANCER TARGET INITIATIVE​

BRIEF-Daiichi Sankyo completes share repurchase

* Says it accumulatively repurchased 15.7 million shares for 50 billion yen in total as of March 22

BRIEF-Fortis Healthcare Gets Court Order Relating To Daiichi Sankyo Co Case

* GETS COURT ORDER RELATING TO DAIICHI SANKYO COMPANY LIMITED CASE

BRIEF-Daiichi Sankyo Initiates Phase 2 Study Of DS-8201

* DAIICHI SANKYO INITIATES PHASE 2 STUDY OF DS-8201 IN PATIENTS WITH HER2-EXPRESSING ADVANCED COLORECTAL CANCER Source text for Eikon: Further company coverage:

BRIEF-Medrx signs joint development contract with DAIICHI SANKYO

* Says it signed a joint development contract with DAIICHI SANKYO COMPANY, LIMITED, regarding development candidates using Nano-sized Colloid Transdermal System owned by the company

BRIEF-Daiichi Sankyo's Regulatory Submission Triggers $20 Mln Milestone Payment To Exelixis​

* CO ‍ANNOUNCES COLLABORATOR DAIICHI SANKYO'S SUBMISSION OF REGULATORY FILING FOR ESAXERENONE (CS-3150) IN JAPAN​

Select another date: